Specific biomarkers, such as PD-L1 expression, tumor mutation burden (TMB), blood TMB (bTMB), CD8+ T cell infiltration, immune signature and mismatch repair (MMR), are predictive biomarkers of patient benefit to ICIs (Dong et al., 2017; Wang et al., 2019). The gene discussed is CD8A; the disease is neoplasm.